Evidence for clinical AI at every stage of deployment.

From onboarding to insight

For suitable enquiries, the intake is more than an administrative form. It becomes the basis of an early strategic readout: where the organisation stands, which evidence is missing, which evaluation pathway is proportionate, and how similar cases have approached related challenges.

• Evaluability status and risk tier
• Likely evidence modules and dependencies
• Missing documents, datasets or governance approvals
• Indicative next step: go / refine / pause
• Optional anonymised patterning against prior engagements once the internal evidence base is mature enough

Useful benchmarks, careful comparisons

We do not promise spurious “industry rankings” off a tiny sample. Early comparative insights are framed carefully: trend observations, similar-case lessons and maturity signals, always anonymised and only when the internal reference set is credible enough to support them.

Evidence should help organisations decide what to do next — not simply produce a score.

An evaluation produces more than a score. We capture the context needed to interpret the evidence later: what was tested, which version, in which setting, against what reference standard, by whom, with which thresholds, what failed, what changed and why.

Over time, these structured traces can form an assurance context layer linking evidence, decisions, versions, settings and outcomes. That gives client teams an auditable organisational memory for re-evaluation, release decisions, incident review and handover.

Evidence becomes more valuable when its provenance and decision context remain visible.

Use established standards where they represent the meaning well.

Where local terms, codes, languages, cadres or workflows are not represented cleanly, preserve them as governed source terms, map them to standard concepts where semantic equivalence exists, and retain the provenance, ambiguity and adjudication needed to interpret that mapping later.

R&D direction: modular African source-term and context vocabularies organised by country, language and domain, with reusable mapping provenance.

We want African evidence to shape global health R&D early enough to influence what gets built, how it is evaluated and what claims are supportable.

sinter.bio has a particular interest in responsibly bringing African clinical data, local contextual knowledge, community priorities and implementation evidence into global health R&D and AI evaluation pipelines.

Evaluation should remain sensitive to language, workflow, infrastructure, disease patterns, population representation and health-system realities. Where community-governed or culturally specific knowledge is relevant, authority, provenance, responsibility, ethics and benefit are explicit parts of the design.

A name from metallurgy, chosen for evidence work

In metallurgy, sintering is the process of forming a stronger material by applying heat or pressure so that particles bond and structure emerges — without simply melting everything into one indistinguishable mass.

That idea captures what sinter.bio is trying to do in clinical AI and health-data assurance. We bring together evidence, context, provenance and local knowledge to produce something stronger and more useful for decision-making, while preserving the identity and meaning of the underlying parts.

Preserve local meaning. Strengthen global usability. Keep the trace of how evidence became a decision.

• Context is not noise. We preserve the setting, user, risk and workflow conditions that shape whether a system works.
• Provenance matters. We keep a trace of what was tested, what evidence was used, who reviewed it and why a decision was made.
• Africa-rooted does not mean isolated. We want African data, contextual knowledge and implementation evidence to inform global health R&D without being flattened or erased.
• Nothing important gets lost. The goal is not to melt every local signal into a generic standard, but to connect them in a way that remains interpretable, auditable and reusable.